What are Jazz Pharmaceuticals's total assets?

Jazz Pharmaceuticals (JAZZ) holds $11.9B in total assets, up 2.8% year over year.

How much debt does Jazz Pharmaceuticals have?

Jazz Pharmaceuticals carries $5.4B in total debt against $4.5B of shareholders' equity, a debt-to-equity ratio of 1.19.

How much cash does Jazz Pharmaceuticals have?

Jazz Pharmaceuticals holds $667.5M in cash and equivalents.

Can Jazz Pharmaceuticals cover its short-term obligations?

Its current ratio is 2.04 — current assets exceed current liabilities.

Where does Jazz Pharmaceuticals's balance sheet data come from?

Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Jazz Pharmaceuticals JAZZ Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$682.7M-71.7%	$2.41B+60.2%	$1.51B+70.9%	$881.48M+49.0%
Accounts receivable, net	$830.7M+15.9%	$716.77M+1.6%	$705.79M+8.3%	$651.49M+15.6%
Inventories	$417M-13.2%	$480.45M-19.5%	$597.04M-16.4%	$714.06M-33.4%
Raw materials	$22M+9.1%	$20.16M-21.2%	$25.6M+23.1%	$20.79M-3.5%
Work in process	$253.4M-18.7%	$311.75M-27.8%	$431.73M-16.6%	$517.67M-41.6%
Finished goods	$141.6M-4.7%	$148.53M+6.3%	$139.71M-20.4%	$175.61M+6.9%
Prepaid expenses and other current assets	$152.5M-14.0%	$177.41M-4.3%	$185.48M+102%	$91.91M-30.1%
Derivative assets	$6.3M+94.4%	$3.24M-85.1%	$21.82M+25.7%	$17.36M—
Total current assets	$4.17B-10.0%	$4.63B+34.7%	$3.44B+31.8%	$2.61B-0.2%
Property and equipment, net	$199.9M+15.3%	$173.41M+2.2%	$169.65M-25.6%	$228.05M-11.2%
Accumulated depreciation	$178.5M+10.2%	$161.96M+21.5%	$133.35M+23.9%	$107.65M+26.1%
Total property and equipment, gross	$378.4M+12.8%	$335.37M+10.7%	$303M-9.7%	$335.7M-1.9%
Operating lease right-of-use assets	$58.9M+9.9%	$53.58M-18.0%	$65.34M-10.9%	$73.33M-15.3%
Goodwill	$1.83B+6.6%	$1.72B-2.1%	$1.75B+3.6%	$1.69B-7.4%
Intangible assets, net	$4.43B-6.9%	$4.76B-12.2%	$5.42B-6.5%	$5.79B-19.0%
Deferred tax assets	$594.5M-12.2%	$676.74M-20.2%	$847.71M-10.2%	$944.34M-27.4%
Other non-current assets	$99M-13.5%	$114.48M+69.7%	$67.46M+22.4%	$55.14M+35.1%
Equity method investments	$4.3M0.0%	$4.3M-8.5%	$4.7M-14.5%	$5.5M—
Long-term investments	$1.05B+81.0%	$580M+383%	$120M—	$0—
Total assets	$11.66B-2.9%	$12.01B+5.4%	$11.39B+5.2%	$10.84B-11.9%
Accounts payable	$122.1M+56.8%	$77.87M-24.2%	$102.75M+13.2%	$90.76M-9.5%
Accrued expenses	$1.03B+13.5%	$910.95M+14.7%	$793.91M-1.2%	$803.26M+20.6%
Accrued compensation	$215.4M+40.7%	$153.13M+26.3%	$121.21M-15.4%	$143.24M-9.8%
Current portion of long-term debt	$1.03B+3,222%	$31M-94.9%	$604.95M+1,851%	$31M0.0%
Income taxes payable	$56.3M+200%	$18.76M-46.5%	$35.07M+355%	$7.72M-19.7%
Accrued interest	$40.7M-2.2%	$41.63M+14.2%	$36.44M+2.3%	$35.61M-26.8%
Total current liabilities	$2.24B+116%	$1.04B-32.4%	$1.54B+64.7%	$933.19M+15.3%
Long-term debt	$4.33B-28.8%	$6.08B+19.0%	$5.11B-10.3%	$5.69B-5.4%
Operating lease liabilities, non-current	$50.9M+30.7%	$38.94M-34.3%	$59.23M-17.6%	$71.84M-17.6%
Other non-current liabilities	$124.4M+43.6%	$86.61M-17.3%	$104.75M-1.9%	$106.81M-8.7%
Common stock	$0-100%	$6K0.0%	$6K0.0%	$6K0.0%
Additional paid-in capital	$4.24B+8.4%	$3.91B+5.8%	$3.7B+6.4%	$3.48B-1.6%
Retained earnings	$646.1M-42.7%	$1.13B+28.3%	$878.66M+19.8%	$733.59M-11.6%
Accumulated other comprehensive income (loss)	-$568.6M+40.0%	-$947.67M-12.5%	-$842.15M+25.2%	-$1.13B-181%
Total stockholders' equity	$4.32B+5.5%	$4.09B+9.5%	$3.74B+21.1%	$3.09B-22.2%
Total liabilities and stockholders' equity	$11.66B-2.9%	$12.01B+5.4%	$11.39B+5.2%	$10.84B-11.9%
Cash Cash Equivalents And Short Term Investments	$2.44B—	——	——	——
Finished goods	$141.6M-4.7%	$148.53M+6.3%	$139.71M-20.4%	$175.61M+6.9%
Other current assets	$323.9M+23.8%	$261.54M-18.5%	$320.81M+20.1%	$267.19M+5.9%
Derivative Assets - Fair Value	$6.3M+94.4%	$3.24M-85.1%	$21.82M+25.7%	$17.36M—
Trading Securities in Marketable Securities	$4.3M0.0%	$4.3M-8.5%	$4.7M-14.5%	$5.5M—
Deferred Tax Assets and Other Non-Current Assets	$99M-13.5%	$114.48M+69.7%	$67.46M+22.4%	$55.14M+35.1%
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments	$4.3M0.0%	$4.3M-8.5%	$4.7M-14.5%	$5.5M—
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——
Finite Lived Intangible Assets - Gross	$8.21B+6.4%	$7.71B-1.1%	$7.8B+3.9%	$7.51B-8.6%
Investments - Amortized Cost Basis	$4.3M0.0%	$4.3M-8.5%	$4.7M-14.5%	$5.5M-99.1%
Net Investment in Lease	$58.9M+9.9%	$53.58M-18.0%	$65.34M-10.9%	$73.33M-15.3%
Deferred tax assets	$869.1M+55.1%	$560.25M+17.2%	$477.83M+27.0%	$376.25M+20.9%
Intangible assets — net	$4.43B-6.9%	$4.76B-12.2%	$5.42B-6.5%	$5.79B-17.2%
Other intangible assets—net	$4.43B-6.9%	$4.76B-12.2%	$5.42B-6.5%	$5.79B-19.0%
Investments	$1.05B+81.0%	$580M+383%	$120M—	$0—
Operating lease right-of-use assets	$58.9M+9.9%	$53.58M-18.0%	$65.34M-10.9%	$73.33M-15.3%
Other non-current assets	$99M-13.5%	$114.48M+69.7%	$67.46M+22.4%	$55.14M+35.1%
Property, plant and equipment, net	$199.9M+15.3%	$173.41M+2.2%	$169.65M-25.6%	$228.05M-11.2%
Operating Lease Right-of-Use Assets in Other Assets	$58.9M+9.9%	$53.58M-18.0%	$65.34M-10.9%	$73.33M-15.3%
Software and Technology Licenses, Net	$99M-13.5%	$114.48M+69.7%	$67.46M+22.4%	$55.14M+35.1%
Accrued Marketing and Advertising Expenses	$15.4M-42.9%	$26.98M+83.0%	$14.74M-20.5%	$18.55M-14.0%
Accrued Royalties (Current)	$47.1M+28.0%	$36.8M+19.9%	$30.71M-46.5%	$57.35M+182%
Other Commercial Liabilities	$1.03B+13.5%	$910.95M+14.7%	$793.91M-1.2%	$803.26M+20.6%
Accrued Liabilities, Current	$1.03B+13.5%	$910.95M+14.7%	$793.91M-1.2%	$803.26M+20.6%
Derivative Liability, Current	$4.2M-58.8%	$10.2M+1,398%	$681K—	$0-100%
Derivative Liabilities - Fair Value	$4.2M-58.8%	$10.2M+1,398%	$681K—	$0-100%
Derivative Liabilities, Gross	$4.2M-58.8%	$10.2M+149%	$4.09M—	——
Derivative Liabilities - Not Offset Policy Election Deduction	$4.2M-58.8%	$10.2M+149%	$4.09M—	——
Professional Service Fees Payable	$23M-12.3%	$26.22M+34.2%	$19.54M-12.3%	$22.28M-1.0%
Debt Maturity - 2024	——	——	——	——
Debt Maturity - 2027	——	——	——	——
Marketing and selling	$15.4M-42.9%	$26.98M+83.0%	$14.74M-20.5%	$18.55M-14.0%
Total debt	$5.43B-12.0%	$6.17B+6.4%	$5.8B-0.4%	$5.82B-5.6%
Total Carrying Value of Debt	——	——	——	——
Additional paid-in capital	$4.24B+8.4%	$3.91B+5.8%	$3.7B+6.4%	$3.48B-1.6%
Capital redemption reserve	$500K+5.7%	$473K0.0%	$473K+0.2%	$472K0.0%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$0-100%	$6K0.0%	$6K0.0%	$6K0.0%
Non-voting euro deferred shares	$100K+81.8%	$55K0.0%	$55K0.0%	$55K0.0%
Unrealized Gains on Investments	$0—	$0—	$0—	$0—
Unrealized Losses on Investments (Before Tax)	$0—	$0—	$0—	$0—
Fair Value Measurement Disclosure	$4.2M—	——	——	——
Clinical trial accruals	$42M-15.9%	$49.96M+11.6%	$44.76M+42.8%	$31.34M—
Accrued construction-in-progress	$14.3M+42.1%	$10.06M+95.7%	$5.14M+55.9%	$3.3M—
Accrued development expenses	$24.4M+5.6%	$23.1M—	——	——
Inventory-related accruals	$34M+33.3%	$25.51M+82.5%	$13.98M+63.2%	$8.57M—
Professional service fees	$23M-12.3%	$26.22M+34.2%	$19.54M-12.3%	$22.28M-1.0%
Rebates and other sales deductions	$459.8M+34.2%	$342.72M+5.2%	$325.71M+4.0%	$313.18M—
Licensing Arrangements	$47.1M+28.0%	$36.8M+19.9%	$30.71M-46.5%	$57.35M+182%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$0—	$0—	$0—	$0—
Gross Unrealized Gains	$0—	$0—	$0—	$0—
Cash, Cash Equivalents, and Short-Term Investments, Amortized Cost	$2.44B—	——	——	——
Long-term debt, gross	——	——	——	——
Deferred Finance Costs Noncurrent Net	$7.6M-19.9%	$9.49M+46.5%	$6.48M-30.0%	$9.25M-23.1%
Deferred income taxes	$594.5M-12.2%	$676.74M-20.2%	$847.71M-10.2%	$944.34M-27.4%
Trading securities, cost	$4.3M0.0%	$4.3M-8.5%	$4.7M-14.5%	$5.5M—
Thereafter	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$3.78B+27.8%	$2.96B+24.2%	$2.38B+39.2%	$1.71B+41.1%
2028	——	——	——	——
2030	——	——	——	——
Remainder of 2026	——	——	——	——
2027	——	——	——	——
2029	——	——	——	——
Gross Carrying Amount	$8.21B+6.4%	$7.71B-1.1%	$7.8B+3.9%	$7.51B-8.6%
2028	——	——	——	——
2029	——	——	——	——
2030	——	——	——	——
2027	——	——	——	——
Remainder of 2026	——	——	——	——
Current portion of lease liabilities	$14.7M-0.5%	$14.78M-24.0%	$19.45M+22.0%	$15.94M—
Other accrued liabilities	$72.8M-6.6%	$77.93M+3.2%	$75.51M+10.0%	$68.67M+15.8%
Prepaid expenses	$152.5M-14.0%	$177.41M-4.3%	$185.48M+102%	$91.91M-30.1%
Sales return reserve	$26.4M-0.1%	$26.43M+29.3%	$20.44M-21.9%	$26.16M—
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Jazz Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Jazz Pharmaceuticals's total assets?: Jazz Pharmaceuticals (JAZZ) holds $11.9B in total assets, up 2.8% year over year.
How much debt does Jazz Pharmaceuticals have?: Jazz Pharmaceuticals carries $5.4B in total debt against $4.5B of shareholders' equity, a debt-to-equity ratio of 1.19.
How much cash does Jazz Pharmaceuticals have?: Jazz Pharmaceuticals holds $667.5M in cash and equivalents.
Can Jazz Pharmaceuticals cover its short-term obligations?: Its current ratio is 2.04 — current assets exceed current liabilities.
Where does Jazz Pharmaceuticals's balance sheet data come from?: Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.